Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does POMALIDOMIDE Cause Thrombophlebitis superficial? 26 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 26 reports of Thrombophlebitis superficial have been filed in association with POMALIDOMIDE (Pomalyst). This represents 0.0% of all adverse event reports for POMALIDOMIDE.

26
Reports of Thrombophlebitis superficial with POMALIDOMIDE
0.0%
of all POMALIDOMIDE reports
2
Deaths
12
Hospitalizations

How Dangerous Is Thrombophlebitis superficial From POMALIDOMIDE?

Of the 26 reports, 2 (7.7%) resulted in death, 12 (46.2%) required hospitalization, and 3 (11.5%) were considered life-threatening.

Is Thrombophlebitis superficial Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for POMALIDOMIDE. However, 26 reports have been filed with the FAERS database.

What Other Side Effects Does POMALIDOMIDE Cause?

Plasma cell myeloma (7,023) Death (6,795) Fatigue (6,530) Pneumonia (5,792) Off label use (3,845) Diarrhoea (3,351) White blood cell count decreased (3,328) Neutropenia (3,029) Rash (2,715) Dyspnoea (2,543)

What Other Drugs Cause Thrombophlebitis superficial?

DROSPIRENONE\ETHINYL ESTRADIOL (160) LENALIDOMIDE (121) ETHINYL ESTRADIOL\ETONOGESTREL (93) RIVAROXABAN (82) YAZ (78) YASMIN (65) TESTOSTERONE (62) HUMAN IMMUNOGLOBULIN G (43) ADALIMUMAB (40) CAPECITABINE (29)

Which POMALIDOMIDE Alternatives Have Lower Thrombophlebitis superficial Risk?

POMALIDOMIDE vs POMALYST POMALIDOMIDE vs PONATINIB POMALIDOMIDE vs PONATINIB\PONATINIB POMALIDOMIDE vs PONESIMOD POMALIDOMIDE vs PORACTANT ALFA

Related Pages

POMALIDOMIDE Full Profile All Thrombophlebitis superficial Reports All Drugs Causing Thrombophlebitis superficial POMALIDOMIDE Demographics